Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and B-Cell Malignancy Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PIK3AP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIK3AP1 Recombinant Protein / Domain Mutants High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PIK3AP1 Products |
| Gene Delivery | PIK3AP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PIK3AP1 Products |
| Benchmark Ab | Anti-PIK3AP1 Recombinant Antibody Recombinant positive control for assay validation. |
View PIK3AP1 Products |
| Validator | PIK3AP1 siRNA Set For target knockdown verification. |
View PIK3AP1 Products |
| Related Target A | PIK3R1 Regulatory subunit p85 of PI3K; binds directly to phosphorylated PIK3AP1 to initiate downstream AKT signaling. |
View PIK3R1 Products |
| Related Target B | MYD88 Key TLR adapter; interacts with PIK3AP1 to link innate immunity with the PI3K pathway. |
View MYD88 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) mapping | Truncated domain proteins (TIR-like, Proline-rich) with >95% purity verified by SDS-PAGE. |
| Downstream AKT pathway activation validation | High-titer Lentiviral particles designed for stable cell line construction and target validation. |
| Lack of Controls | Clinical Benchmark Antibodies included as positive reference controls. |
| False Positives in Small Molecule Screens | Validated siRNA set included for target-specific knock-down control. |
Live PIK3AP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PIK3AP1 therapeutics is intensifying, with major players shifting focus from traditional systemic kinase inhibitors to targeted intracellular adaptors. As first-generation therapies targeting the broader PI3K pathway reach clinical maturity, the next wave of R&D is targeting PIK3AP1 (BCAP) to selectively modulate TLR and BCR-mediated inflammatory signaling without systemic PI3K toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Institutes, Biotech Startups | Autoimmune Diseases, B-Cell Lymphoma | Biochemical Binding Assays (Need high-purity recombinant PIK3AP1 domains) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Pioneers | Refractory Inflammatory Disorders | Ubiquitination & Degradation Assays (Need sequence-verified Lentivirus for reporter lines) |
| RNA Therapeutics (siRNA/ASO) | RNAi Developers | Macrophage-driven Inflammatory Diseases | Target Knockdown Validation (Need sequence-specific siRNA Sets) |